Drug intelligence / Profile preview

nivolumab + cyclophosphamide

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, and cyclophosphamide, an alkylating agent. Nivolumab blocks the PD-1 pathway, helping the immune system recognize and attack cancer cells, while cyclophosphamide at metronomic doses provides both immunomodulatory and antiangiogenic effects. This combination is being investigated for various cancer types, particularly in pediatric patients with refractory/relapsing solid tumors.

Brand names: Opdivo + Cytoxan
Other names: cyclophosphamide and nivolumabcyclophosphamide plus nivolumab

Targets

DNAPDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on nivolumab + cyclophosphamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nivolumab + cyclophosphamide.

Explore the full profile